SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 226 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $3,000 | -62.5% | 111 | -62.1% | 0.00% | – |
| Q3 2021 | $8,000 | -100.0% | 293 | -99.9% | 0.00% | -100.0% |
| Q2 2021 | $16,080,000 | +92.7% | 522,260 | +63.9% | 0.10% | +76.3% |
| Q1 2021 | $8,344,000 | -74.5% | 318,706 | -75.5% | 0.06% | -80.5% |
| Q4 2020 | $32,759,000 | +59.8% | 1,302,015 | +32.4% | 0.30% | +17.0% |
| Q3 2020 | $20,494,000 | -9.8% | 983,395 | +2.8% | 0.26% | -13.1% |
| Q2 2020 | $22,727,000 | +152.0% | 956,924 | +90.9% | 0.30% | +96.1% |
| Q1 2020 | $9,020,000 | -26.8% | 501,392 | -3.4% | 0.15% | +10.9% |
| Q4 2019 | $12,317,000 | -46.1% | 519,271 | -37.6% | 0.14% | -49.4% |
| Q3 2019 | $22,870,000 | +329.2% | 832,247 | +416.7% | 0.27% | +337.1% |
| Q2 2019 | $5,329,000 | +177533.3% | 161,057 | +101834.8% | 0.06% | – |
| Q2 2015 | $3,000 | – | 158 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |